Jennifer Robinson, professor of epidemiology in the University of Iowa College of Public Health and director of the Preventive Intervention Center, was the lead researcher on a team from the National Lipid Association that issued a statement paper providing clinicians with new guidance for the use of statins in select patients.

The guidance regarded lowering the price of the LDL-lowering drug PCSK9 mAbs in three groups of patients with high levels of LDL cholesterol, in order to increase access to those statins.